Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Sell
44
BNTX Quote, Financials, Valuation and Earnings
Last price:
$111.98
Seasonality move
:
4.91%
Day range:
$111.93 - $114.67
52-week range:
$76.53 - $131.49
Dividend yield:
0%
P/E ratio:
191.55x
P/S ratio:
8.18x
P/B ratio:
1.26x
Volume:
457.5K
Avg. volume:
670.3K
1-year change:
14.68%
Market cap:
$26.8B
Revenue:
$4.1B
EPS (TTM):
-$2.11
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
$193.2M | -$1.95 | -24.68% | -74.38% | $137.63 |
|
AKTX
Akari Therapeutics PLC
|
-- | -- | -- | -- | -- |
|
MRNA
Moderna
|
$194.3M | -$2.92 | -63.53% | -79.68% | $68.01 |
|
PFE
Pfizer
|
$14.3B | $0.72 | 27.51% | 12.4% | $31.18 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
TRIB
Trinity Biotech PLC
|
$16M | -$0.28 | 22.88% | -58.33% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
$111.93 | $137.63 | $26.8B | 191.55x | $0.00 | 0% | 8.18x |
|
AKTX
Akari Therapeutics PLC
|
$1.19 | -- | $29.4M | -- | $0.00 | 0% | -- |
|
MRNA
Moderna
|
$34.06 | $68.01 | $13.1B | -- | $0.00 | 0% | 2.61x |
|
PFE
Pfizer
|
$26.30 | $31.18 | $149B | 35.54x | $0.42 | 6.39% | 2.52x |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.38 | -- | $3.1M | -- | $0.25 | 0% | -- |
|
TRIB
Trinity Biotech PLC
|
$0.83 | -- | $22.7M | -- | $0.00 | 0% | 0.15x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BNTX
BioNTech SE
|
1.26% | 0.632 | 0.96% | 7.10x |
|
AKTX
Akari Therapeutics PLC
|
-- | -0.056 | -- | -- |
|
MRNA
Moderna
|
-- | -0.054 | -- | 3.95x |
|
PFE
Pfizer
|
41.92% | 0.489 | 40.56% | 0.64x |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.581 | -- | -- |
|
TRIB
Trinity Biotech PLC
|
147.47% | -2.949 | 785.94% | 0.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
AKTX
Akari Therapeutics PLC
|
-- | -$1.9M | -- | -- | -- | -$1.5M |
|
MRNA
Moderna
|
$1.3B | -$70M | -17.44% | -17.44% | 1.46% | -$1.7B |
|
PFE
Pfizer
|
$12.4B | $5.3B | 2.66% | 4.63% | 31.06% | $6.1B |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
TRIB
Trinity Biotech PLC
|
$5.3M | -$2.2M | -45.03% | -- | -11.29% | -$6.3M |
BioNTech SE vs. Competitors
-
Which has Higher Returns BNTX or AKTX?
Akari Therapeutics PLC has a net margin of 15.91% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -2.35% beat Akari Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE85.63% $0.89 $21.6B AKTXAkari Therapeutics PLC-- -$0.24 -- -
What do Analysts Say About BNTX or AKTX?
BioNTech SE has a consensus price target of $137.63, signalling upside risk potential of 22.97%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 6628.34%. Given that Akari Therapeutics PLC has higher upside potential than BioNTech SE, analysts believe Akari Therapeutics PLC is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE12 5 0 AKTXAkari Therapeutics PLC0 0 0 -
Is BNTX or AKTX More Risky?
BioNTech SE has a beta of 0.182, which suggesting that the stock is 81.764% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.789, suggesting its less volatile than the S&P 500 by 21.114%.
-
Which is a Better Dividend Stock BNTX or AKTX?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or AKTX?
BioNTech SE quarterly revenues are $1.4B, which are larger than Akari Therapeutics PLC quarterly revenues of --. BioNTech SE's net income of $217.9M is higher than Akari Therapeutics PLC's net income of -$2.9M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.18x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.18x 191.55x $1.4B $217.9M AKTXAkari Therapeutics PLC-- -- -- -$2.9M
-
Which has Higher Returns BNTX or MRNA?
Moderna has a net margin of 15.91% compared to BioNTech SE's net margin of 0.7%. BioNTech SE's return on equity of -2.35% beat Moderna's return on equity of -17.44%.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE85.63% $0.89 $21.6B MRNAModerna72.29% $0.03 $11.9B -
What do Analysts Say About BNTX or MRNA?
BioNTech SE has a consensus price target of $137.63, signalling upside risk potential of 22.97%. On the other hand Moderna has an analysts' consensus of $68.01 which suggests that it could grow by 99.66%. Given that Moderna has higher upside potential than BioNTech SE, analysts believe Moderna is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE12 5 0 MRNAModerna5 14 1 -
Is BNTX or MRNA More Risky?
BioNTech SE has a beta of 0.182, which suggesting that the stock is 81.764% less volatile than S&P 500. In comparison Moderna has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.715%.
-
Which is a Better Dividend Stock BNTX or MRNA?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or MRNA?
BioNTech SE quarterly revenues are $1.4B, which are smaller than Moderna quarterly revenues of $1.9B. BioNTech SE's net income of $217.9M is higher than Moderna's net income of $13M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.18x versus 2.61x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.18x 191.55x $1.4B $217.9M MRNAModerna2.61x -- $1.9B $13M
-
Which has Higher Returns BNTX or PFE?
Pfizer has a net margin of 15.91% compared to BioNTech SE's net margin of 25.23%. BioNTech SE's return on equity of -2.35% beat Pfizer's return on equity of 4.63%.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE85.63% $0.89 $21.6B PFEPfizer70.27% $0.78 $159.2B -
What do Analysts Say About BNTX or PFE?
BioNTech SE has a consensus price target of $137.63, signalling upside risk potential of 22.97%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 18.54%. Given that BioNTech SE has higher upside potential than Pfizer, analysts believe BioNTech SE is more attractive than Pfizer.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE12 5 0 PFEPfizer7 13 1 -
Is BNTX or PFE More Risky?
BioNTech SE has a beta of 0.182, which suggesting that the stock is 81.764% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.
-
Which is a Better Dividend Stock BNTX or PFE?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.39% to investors and pays a quarterly dividend of $0.42 per share. BioNTech SE pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or PFE?
BioNTech SE quarterly revenues are $1.4B, which are smaller than Pfizer quarterly revenues of $17.7B. BioNTech SE's net income of $217.9M is lower than Pfizer's net income of $4.5B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Pfizer's PE ratio is 35.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.18x versus 2.52x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.18x 191.55x $1.4B $217.9M PFEPfizer2.52x 35.54x $17.7B $4.5B
-
Which has Higher Returns BNTX or TCBP?
TC BioPharm (Holdings) PLC has a net margin of 15.91% compared to BioNTech SE's net margin of --. BioNTech SE's return on equity of -2.35% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE85.63% $0.89 $21.6B TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About BNTX or TCBP?
BioNTech SE has a consensus price target of $137.63, signalling upside risk potential of 22.97%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 533.25%. Given that TC BioPharm (Holdings) PLC has higher upside potential than BioNTech SE, analysts believe TC BioPharm (Holdings) PLC is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE12 5 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is BNTX or TCBP More Risky?
BioNTech SE has a beta of 0.182, which suggesting that the stock is 81.764% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BNTX or TCBP?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. BioNTech SE pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or TCBP?
BioNTech SE quarterly revenues are $1.4B, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. BioNTech SE's net income of $217.9M is higher than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.18x versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.18x 191.55x $1.4B $217.9M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
-
Which has Higher Returns BNTX or TRIB?
Trinity Biotech PLC has a net margin of 15.91% compared to BioNTech SE's net margin of -31.41%. BioNTech SE's return on equity of -2.35% beat Trinity Biotech PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BNTXBioNTech SE85.63% $0.89 $21.6B TRIBTrinity Biotech PLC35.03% -$0.46 $55.5M -
What do Analysts Say About BNTX or TRIB?
BioNTech SE has a consensus price target of $137.63, signalling upside risk potential of 22.97%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1715.98%. Given that Trinity Biotech PLC has higher upside potential than BioNTech SE, analysts believe Trinity Biotech PLC is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings BNTXBioNTech SE12 5 0 TRIBTrinity Biotech PLC0 0 0 -
Is BNTX or TRIB More Risky?
BioNTech SE has a beta of 0.182, which suggesting that the stock is 81.764% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 1.006, suggesting its more volatile than the S&P 500 by 0.60500000000001%.
-
Which is a Better Dividend Stock BNTX or TRIB?
BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BNTX or TRIB?
BioNTech SE quarterly revenues are $1.4B, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. BioNTech SE's net income of $217.9M is higher than Trinity Biotech PLC's net income of -$4.8M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 8.18x versus 0.15x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BNTXBioNTech SE8.18x 191.55x $1.4B $217.9M TRIBTrinity Biotech PLC0.15x -- $15.2M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
